ArticleFrontiers in medicine2025
P3-GemOx as a novel immunochemotherapy candidate in NK/T-cell lymphoma management.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Natural killer/T-cell lymphoma (NKTL) is a rare disease that shows suboptimal responses to existing therapies. This study reports the efficacy of the P3-GemOx regimen compared to the traditional PP-GemOx regimen in advanced NKTL. Methods: Eleven patients received the P3-GemOx regimen [mitoxantrone hydrochloride liposome (Plm60) combined with PP-GemOx (anti-PD-1 antibody, pegaspargase, gemcitabine, and oxaliplatin)] every 3-4 weeks, with a median of 3 cycles (range: 1-4). Another eleven patients received the PP-GemOx regimen every 3-4 weeks, with a median of 4 cycles (range: 2-6). Treatment response was assessed using 18F-FDG-PET with CT or MRI. Results: All patients treated with P3-GemOx responded, with nine achieving complete remission (CR) and two partial remission (PR), yielding an overall response rate (ORR) of 100%. Seven of these patients underwent hematopoietic stem cell transplantation (HSCT). In the PP-GemOx group, the ORR was 63.6%, and no patients underwent HSCT. All adverse events were manageable and resolved. Discussion: The P3-GemOx regimen demonstrates superior efficacy over the PP-GemOx regimen in advanced NKTL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.